My attitude is now clearly glass half empty. We are cash strained, our flagship drug revealed to be flawed and back in dosing trials, our stock is blowing in the wind. I am looking for an exit point around ASCO, praying for a b/o. And yes, even a rumor!! And I'm serious about that.
What's with the old data at ASCO? The ASCO data being presented: 8 months old for GIST and '112, 5months for Phase 1, the failed EPIC trial 7 months, and good ol PACE, up to date, complete with recent 'Iclusig events' and dose reduction data. We can only hope this is enough to attract offers.
Q1 was telling. Europe won't be living up to its billing, label review coming. Ever more careful docs (1/3) experimenting at 15mg starting doses. T315I market underserved. No quick fixes. Marty did a great job at obsfucating the numbers. So much spin, and 'reaching 400 patients commercially' is not the same as 400 pod.
Last night, there was discussion that Denner might have to file a 13-d if he wants out. Let's hope he has to file. If so, that is tremendous leverage on Berger. Just the threat removes any hope of any equity infusion. Berger knows this and will have to sell. Denner wants his money sooner than later. Forget the 2 and 3 year recovery plans.
Folks, we trade now at $6.60, and have no strength there. Hard to find one analyst ascribing much value to GIST, or to '113, or the mystery molecule. I am starting to believe them. BIC means very little when the inds are 2+ years away from dollar one of revenue, with other drugs already approved. Those blogs might warm our hearts, they aren't worth much to the stock price.
I don't know how we do it, but we have to put the heat on Berger. He must sell. The threat of that is the only reason we aren't in the $5's and 4's, and thank goodness for that.
